Evidence map›Paper›PMID 42618668›Full record

ArticleHeart and vessels2026

Prognostic implications of a four-group classification based on estimated plasma volume status and creatinine in acute heart failure.

Ran Sumida, Daisuke Kitano, Saki Mizobuchi, Masatsugu Miyagawa, Yutaka Koyama, Hidesato Fujito, Riku Arai, Takumi Hatta, Keisuke Kojima, Yuki Saito and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Heart and vessels, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ran SumidaDivision of Cardiology, Department of Medicine, Nihon University School of Medicine Itabashi Hospital, 30-1 Oyaguchi-kamicho, Itabashi-ku, Tokyo, 173-8610, Japan.
Daisuke KitanoDivision of Cardiology, Department of Medicine, Nihon University School of Medicine Itabashi Hospital, 30-1 Oyaguchi-kamicho, Itabashi-ku, Tokyo, 173-8610, Japan. kitano.daisuke@nihon-u.ac.jp.ORCID http://orcid.org/0000-0003-1791-8398
Saki MizobuchiDivision of Cardiology, Department of Medicine, Nihon University School of Medicine Itabashi Hospital, 30-1 Oyaguchi-kamicho, Itabashi-ku, Tokyo, 173-8610, Japan.
Masatsugu MiyagawaDivision of Cardiology, Department of Medicine, Nihon University School of Medicine Itabashi Hospital, 30-1 Oyaguchi-kamicho, Itabashi-ku, Tokyo, 173-8610, Japan.
Yutaka KoyamaDivision of Cardiology, Department of Medicine, Nihon University School of Medicine Itabashi Hospital, 30-1 Oyaguchi-kamicho, Itabashi-ku, Tokyo, 173-8610, Japan.
Hidesato FujitoDivision of Cardiology, Department of Medicine, Nihon University School of Medicine Itabashi Hospital, 30-1 Oyaguchi-kamicho, Itabashi-ku, Tokyo, 173-8610, Japan.
Riku AraiDivision of Cardiology, Department of Medicine, Nihon University School of Medicine Itabashi Hospital, 30-1 Oyaguchi-kamicho, Itabashi-ku, Tokyo, 173-8610, Japan.
Takumi HattaDivision of Cardiology, Department of Medicine, Nihon University School of Medicine Itabashi Hospital, 30-1 Oyaguchi-kamicho, Itabashi-ku, Tokyo, 173-8610, Japan.
Keisuke KojimaDivision of Cardiology, Department of Medicine, Nihon University School of Medicine Itabashi Hospital, 30-1 Oyaguchi-kamicho, Itabashi-ku, Tokyo, 173-8610, Japan.
Yuki SaitoDivision of Cardiology, Department of Medicine, Nihon University School of Medicine Itabashi Hospital, 30-1 Oyaguchi-kamicho, Itabashi-ku, Tokyo, 173-8610, Japan.
Kazuto ToyamaDivision of Cardiology, Department of Medicine, Nihon University School of Medicine Itabashi Hospital, 30-1 Oyaguchi-kamicho, Itabashi-ku, Tokyo, 173-8610, Japan.
Yasuo OkumuraDivision of Cardiology, Department of Medicine, Nihon University School of Medicine Itabashi Hospital, 30-1 Oyaguchi-kamicho, Itabashi-ku, Tokyo, 173-8610, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We evaluated the prognostic value of a four-group classification combining estimated plasma volume status (ePVS) and serum creatinine (Cre) in patients hospitalized for acute decompensated heart failure (ADHF). We analyzed 914 patients from the SAKURA HF Registry-2 enrolled between September 2018 and December 2023. At discharge, patients were stratified into four groups using ePVS (cutoff, 5.5 mL/g) and Cre (cutoff, 1.1 mg/dL): low-ePVS/low-Cre (n = 285), high-ePVS/low-Cre (n = 136), low-ePVS/high-Cre (n = 263), and high-ePVS/high-Cre (n = 230). The primary endpoint was a composite of all-cause mortality or heart failure rehospitalization. Multivariable Cox models were adjusted for clinical, laboratory, echocardiographic, and discharge-medication covariates. Median age was 74 years and 68% were men. Over a median follow-up of 368 days (interquartile range [IQR], 89-548), 349 patients (38.2%) experienced the primary endpoint, with significant differences among groups (log-rank p < 0.001). In multivariable models, compared with low-ePVS/low-Cre, risk was higher in high-ePVS/low-Cre (hazard ratio [HR] 2.38, 95% confidence interval [CI] 1.31-4.30; p = 0.004) and high-ePVS/high-Cre (HR 1.98, 95% CI 1.12-3.48; p = 0.018), but not in low-ePVS/high-Cre (HR 1.62, 95% CI 0.94-2.79; p = 0.08). A discharge-based ePVS-Cre classification provided clinically relevant risk stratification after ADHF. Elevated ePVS despite non-elevated serum creatinine independently predicted adverse outcomes. When ePVS was low, the excess risk associated with elevated creatinine was attenuated after adjustment, whereas concomitant elevation of ePVS and creatinine remained a high-risk category. This simple bedside framework may support discharge risk assessment.

Indexed as

Estimated plasma volume statusHeart failureRisk stratificationSerum creatinine

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.